Anticancer drugs off label used of: What do the experts think about?;Prescriptions hors AMM en cancérologie: Qu'en pensent les experts?

Bulletin du Cancer

Volumn 91, Issue 10, 2004, Pages 769-777

  Debrix, Isabelle ^a   André, Thierry ^a   Becker, Annie ^a   Lotz, Jean Pierre ^a   Gligorov, Joseph ^a   Boukari, Yasmine ^a   Milleron, Bernard ^a   Pene, Françoise ^b   Flahault, Antoine ^a   Bouleuc, Carole ^c   Bugat, Roland ^d   Casagrande, Thierry ^a   Colin, Philippe ^e   Dorval, Thierry ^c   Goldwasser, François ^f   Levy, Éric ^g   Mignot, Laurent ^h   Morère, Jean François ⁱ   Morvan, François ^j   Serin, Daniel ^k   Zelek, Laurent ^l   more..

^a Pharmacie ^*

^b HÔPITAL TENON   (France)

^c INSTITUT CURIE   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e Clinique Courlancy   (France)

^f Institut Curie ^*  (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h FOCH HOSPITAL   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j CENTRE HOSPITALIER RENÉ DUBOS   (France)

^k INSTITUT SAINTE CATHERINE   (France)

^l HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Anticancer drugs; Drugs well used; Experts; External audit; Off label used

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN; TRASTUZUMAB; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CONSENSUS; DRUG LABELING; ECONOMIC ASPECT; EXPERT SYSTEM; HEALTH CARE FINANCING; HUMAN; MEDICAL AUDIT; MEDICAL ETHICS; MEDICAL EXPERT; PRESCRIPTION; RESOURCE ALLOCATION;

ANTINEOPLASTIC AGENTS; DRUG LABELING; HUMANS; MEDICAL AUDIT; NEOPLASMS; PHARMACY AND THERAPEUTICS COMMITTEE; PRESCRIPTIONS, DRUG;

EID: 9244220150     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Debrix I, Andre T, Flahault A, Kalu O, Gligorov J, Lotz JP, et al. Évaluation du bon usage des anticancéreux: les limites des indications AMM. Bull Cancer 2004; 91: 437-43.
2. Tournigand C, André T, Louvet C, Quinaux E, Achille E, Lledo G, et al. Folfiri followed by Folfox versus Folfox followed by Folfiri in metastatic colorectal cancer (MCRC). J Clin Oncol 2004; 22: 229-37.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
4. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-30.
5. Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2 (+) metastatic breast cancer. Oncologist 2002; 7: 410-7.
6. Kerbrat P, Lhomme C, Fervers B, Guastalla JP, Thomas L, Basuyau JP, et al. Standards, options, and recommendations for initial management of patients with malignant ovarian epithelial tumors. Press Med 2000; 29: 2116-27.
7. Parmar MK, Ledermann JA, Colombo N, Du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-106.
8. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-66.
9. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21 [abstr. 141].
10. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, Downer SM. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 1990; 300: 1458-60.
11. Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L. Decision framework for chemotherapy interventions for metastatic non small cell lung cancer. J Natl Cancer Inst 2000; 92: 1321-9.
12. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care BSC vs BSC in inoperable non small-cell lung cancer: a randomized trial with quality of life as primary outcome. Br J Cancer 2000; 83: 447-53.
13. Vansteenkiste J, Vandenbroack J, Nackaerts K. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non small-cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesin to gemcitabine. Lung Cancer 2003; 40: 191-9.
14. Evidence-Based Medicine Working Group. Evidence-based medicine. JAMA 1992; 268: 2420-5.
15. Sacket DL. Evidence-based medicine: what it is and what it isn't. Br Med J 1996; 312: 71-2.
16. Canadian Task force on the Periodic Health Examination. The Periodic Health Examination. Can Med Assoc J 1979; 121: 1193-233.
17. Levy C, Bonastre J. Le coût de la chimiothérapie. Bull Cancer 2003; 90: 976-82.